Kimberly-Clark spinoff Halyard Health, and its suite of protective gear, is a beneficiary of the Ebola fears striking West Africa and the U.S. airwaves. The stock is up a little more than a dollar since Monday's IPO, and stands at $38.72 on the New York Stock Exchange prior to market open today.
Gauss Surgical, maker of a real-time monitor app for blood loss during surgery, raised $1.5 million by selling equity in the company. The total offering could go as high as $2 million, according to a SEC filing.
ReShape Medical said about a year ago that it had positive U.S. pivotal obesity data for its ReShape Integrated Dual Balloon. Now it has offered a glimpse of that data for the first time, ahead of an FDA review that's expected to come during the first half of 2015.
When the Jumpstart Our Business Startups (JOBS) Act became law, no one was quite sure what, if anything, it would do in practice to encourage the financing of innovative companies. One firm is plowing ahead into this uncharted territory, aiming to push beyond the often consumer-oriented efforts of major crowdfunding sites like Kickstarter and Indiegogo.
Medical device startup Force Impact Technologies designed a mouthguard that can provide real-time alerts on concussions during high-impact activities to coaches and medical professionals.
Medtronic kicked off the commercialization of its Resolute Onyx drug-eluting stent in Europe today. The device will also be launched in selected countries around the world that recognize the CE mark, but not the U.S., where FDA approval is required.
Boston Scientific is shoring up for the first federal trials over its transvaginal mesh devices, countering claims from women who say the products were faulty and caused them injury.
Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger
Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.
Rock Health announced a shift in strategy as it proclaimed the launch of its third and largest seed fund for med tech startups. All Rock Health portfolio companies will now receive $250,000 in funding, instead of $100,000, but the number of companies supported will decrease.
Entrepreneur Jonathan Rothberg's startup company Butterfly Network is working on a new imaging device the size of an iPhone that you will be able to hold up to a person's chest and see real-time, 3-D images of their heart beating.
Covidien will be managed as a fourth group within Medtronic's corporate structure. The acquired company will remain intact, with the exception of its peripheral and neurovascular businesses. Covidien's peripheral business will join Medtronic's aortic and peripheral unit within Medtronic's cardiac and vascular group while the neurovascular business will become part of the restorative therapies group.
Making medical device prototypes using 3-D injection molding, rather than traditional aluminum molds, could reduce the costs and time associated with the product creation and iteration process. That's what major 3-D printer Stratasys is betting on with its new partnership with Worrell.
Tech development company Allied Minds entered a licensing agreement with Columbia University to form Seamless Devices.
GreatCall, maker of mobile health and safety apps, is adding the AliveCor Heart Monitor for detecting atrial fibrillation to its offerings. Alivecor's electrocardiogram can now be mounted to back of the GreatCall3 smartphone and used with the AliveECG app.
Long plagued by suits over its metal-on-metal hip implants, Johnson & Johnson is weighing a $250 million settlement to resolve more claims that were not covered under an earlier accord.
The long-anticipated acquisition of Biomet by Zimmer Holdings is almost slated to close. The resulting entity will be known as Zimmer Biomet; it has already unveiled a planned new organizational structure and an executive team that draws heavily on the soon-to-be-incorporated Biomet. The deal to create this musculoskeletal giant is expected to close during the first quarter of 2015.
Smith & Nephew officials stressed their plan to sell midtier orthopedics in emerging markets during the company's Q3 earnings call, but many are wondering about rumors that CEO Olivier Bohuon is among the contenders in Sanofi's CEO search.
Endoscopy system maker EndoChoice is the latest in a series of planned big-ticket med tech IPOs. The startup reportedly plans to file for an IPO on Nasdaq to raise $100 million to $150 million and value the company at as much as $600 million.
Unfortunately for foreign devicemakers, import substitution appears to be one of the means by which China intends to achieve its goal of creating 10 med tech breadwinners worth 5 billion yuan ($820 million) apiece by 2020.
For the 9th year running, Cleveland Clinic announced its list of top 10 medical innovations likely to make a substantial impact on improving patient care in the coming year.